Otros idiomas Invex Therapeutics Ltd

Acciones

IXC

AU0000048621

Mercado cerrado - Australian S.E. Otros sitios de cotización 07:34:05 02/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,08 ^AUD	-2,44 %		-2,44 %	-1,23 %

16/02	Invex Therapeutics reduce sus pérdidas en el primer semestre fiscal gracias a un menor gasto en I+D	MT
15/02	Invex Therapeutics Ltd informa de los resultados de beneficios del semestre finalizado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Australia's Tax Agency Publishes Ruling on Invex Therapeutics' Capital Return	20/03
Invex Therapeutics Narrows Fiscal H1 Loss on Lower R&D Expenses	16/02
Invex Therapeutics Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	15/02
Invex Therapeutics, Peptron End Collaboration, Manufacturing Deal	22/12
Invex Therapeutics to Secure European Patent Grant for Neurological Medication	22/11
Invex Therapeutics Ltd Announces Appointment of David Wheeler as Non-Executive Director	08/11
Invex Therapeutics Ltd Reports Earnings Results for the Full Year Ended June 30, 2023	17/08/23
Invex Therapeutics Ltd Announces Board Changes	03/07/23
Invex Therapeutics Jumps 19% After Securing Second European Orphan Drug Designation for Exenatide	23/06/23
Invex Therapeutics Secures Approval for IIH EVOLVE Phase III Trial in France; Shares Rise 7%	21/04/23
Israel's Ministry of Health Approves Invex Therapeutics' IIH EVOLVE Clinical Trial	20/04/23
Invex Therapeutics Secures Clearance for Phase 2 Neurological Trial in Germany; Shares Rise 4%	20/03/23
Invex Therapeutics Ltd Announces the Approval to Commence the IIH EVOLVE Phase III Clinical Trial	19/03/23
Invex Therapeutics Ltd. Announces the Publication of the Invex Phase II 'Pressure' Clinical Trial	13/03/23
Invex Therapeutics More Than Doubles Fiscal H1 Loss	17/02/23
Invex Therapeutics Ltd Reports Earnings Results for the Half Year Ended December 31, 2022	16/02/23
Invex Therapeutics Opens First US Clinical Trial Site in Texas	19/01/23
Invex Therapeutics Ltd Announces First US Clinical Site Activated in IIH Evolve Phase III Clinical Trial	18/01/23
Invex Therapeutics Gains European Regulator Approval for Pediatric Plan	14/12/22
Invex Therapeutics Ltd Receives Approval for Paediatric Plan from the EMA	13/12/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Invex Therapeutics Ltd

Acciones

IXC

AU0000048621

Otros idiomas

Filtros